Everything you need to know about finding providers, listing your business, and using MyDrugTesting.com.
Rapid or instant drug tests are convenient tools that provide visual results within minutes of sample collection. These point-of-collection tests are designed to be sensitive, so they can quickly identify samples that are clear of substances. If a rapid test yields a negative result, the process concludes immediately, saving time and administrative costs. Despite their convenience, rapid tests are intended only as preliminary screenings because they are more susceptible to false positives. They do not identify specific substances as precisely as a laboratory. Therefore, any result that is not clearly negative on a rapid test must be sent to a certified laboratory for confirmation. Laboratory testing uses advanced technology to confirm results. Certified labs perform a secondary confirmation test that identifies and measures specific drug molecules, which helps reduce false positives caused by cross-reacting substances. Laboratory testing typically takes one to three days and provides the legally defensible results used for employment decisions.
View →
Hair follicle testing analyzes a small sample of hair, typically about 100 strands cut close to the scalp, to detect drug use. When someone uses drugs, trace metabolites circulate in the bloodstream and become embedded in the hair as it grows. A standard 1.5-inch sample can reveal a pattern of drug use over approximately the past 90 days, far longer than the detection window of urine or saliva tests. The main benefit is the extended detection window. Hair samples are collected under direct observation and are less affected by a few days of abstinence before the test. This makes hair testing popular for pre-employment screening and situations where employers want insight into longer-term patterns rather than recent use. The tradeoffs are that it costs more than urine testing, results take longer, and it won't detect very recent use, since drugs take about 5 to 7 days to appear in hair. Note that hair testing is not currently authorized for DOT-regulated testing, which still requires urine or oral fluid specimens.
View →
A negative-dilute result is a negative DOT drug test in which the laboratory also found the urine specimen to be dilute. 49 CFR 40.3 defines a dilute specimen as "a urine specimen with creatinine and specific gravity values that are lower than expected for human urine." Under 49 CFR 40.155, the Medical Review Officer (MRO) reports to the Designated Employer Representative (DER) that the specimen is dilute and explains the employer's obligations and choices under 49 CFR 40.197. That section sets two paths. When the creatinine concentration is at least 2 mg/dL but no more than 5 mg/dL, the MRO directs an immediate recollection under direct observation, and the employer conducts it immediately (49 CFR 40.155(c), 40.197(b)(1)). When the creatinine concentration is greater than 5 mg/dL, the employer may, but is not required to, direct the employee to take another test immediately, and that recollection is not directly observed unless another basis for direct observation applies. Section 40.197 states that an employer that uses optional retests must treat all employees the same and inform employees of its policy in advance, although it may set different policies for different types of tests. The result of the directed test, not the earlier test, is the test result of record. Declining a directed test is a refusal to test. A positive result that is also dilute is treated as a verified positive. Related topics are covered in When Is a DOT Urine Collection Directly Observed? and What Counts as Refusing a DOT Drug Test?. The MyDrugTesting.com directory lists MROs, collection sites and other drug testing providers that can be searched by location and service.
View →
An invalid result is defined in 49 CFR 40.3 as the result reported by an HHS-certified laboratory "when a positive, negative, adulterated, or substituted result cannot be established for a specific drug or specimen validity test." Under 49 CFR 40.90, the laboratory applies the invalid result criteria in the HHS Mandatory Guidelines and reports the reason the result is invalid. Under 49 CFR 40.159, the MRO first discusses the result with a laboratory certifying scientist to decide whether the specimen should be tested at another HHS-certified laboratory. If no further testing is needed, the MRO contacts the employee, asks about medications and determines whether there is a medical explanation for the invalid result. Under 49 CFR 40.159(a)(4) and (a)(5), the MRO cancels the test in either case. With an acceptable explanation, no further action is required unless a negative result is needed, as in pre-employment, return-to-duty and follow-up tests. Without one, the MRO reports that a second collection must take place immediately under direct observation. If the employee admits adulterating or substituting the specimen, the MRO reports a refusal to test. A related result is explained in What Does a Cancelled DOT Drug Test Mean?. Employers and employees can search the MyDrugTesting.com directory by location and service to find collection sites, laboratories and MROs.
View →
A cancelled drug test is "neither a positive nor a negative test," according to the definition in 49 CFR 40.3. The term covers a test with a problem that cannot be or has not been corrected, or a test that Part 40 otherwise requires to be cancelled. Under 49 CFR 40.199, some problems, called fatal flaws, always cause a test to be cancelled. Examples listed in the rule include a missing CCF, specimen ID numbers on the bottle and the CCF that do not match, and a broken or tampered bottle seal when the split specimen cannot be re-designated. Under 49 CFR 40.207, an employer must not attach the consequences of a positive test to a cancelled test, and a cancelled test cannot serve as the negative result needed for a pre-employment, return-to-duty or follow-up test. The employer also must not direct a recollection because a test was cancelled, except where a negative result is needed or another provision of Part 40 requires another test. A cancelled test does not count toward the employer's minimum random testing rate and is not a valid basis for a non-DOT test. For a correctable flaw, only the MRO who cancelled the test can reverse the cancellation, within 60 days of the cancellation or later with ODAPC permission. A related result is explained in What Does an Invalid DOT Drug Test Result Mean?. The MyDrugTesting.com directory can be searched by location and service to find collection sites and other drug testing providers.
View →
Under 49 CFR 40.121, only a licensed physician (Doctor of Medicine or Osteopathy) may act as a Medical Review Officer (MRO) in the DOT drug testing program. A physician licensed in any U.S., Canadian or Mexican jurisdiction who meets the other requirements may review results for covered employees wherever they are located. The rule requires knowledge of and clinical experience in controlled substance abuse disorders, knowledge of adulterated, substituted and invalid specimens, and current knowledge of Part 40, the DOT MRO Guidelines and the DOT agency rules for the employers served. Before performing MRO functions, the physician completes qualification training on the subjects listed in 40.121(c) and passes an examination given by a nationally recognized MRO certification board or subspecialty board. Requalification training and another examination follow during each five-year period after the first examination. Under 40.121(e), the MRO keeps documentation showing that all requirements are currently met and provides it on request to DOT agency representatives and to employers and C/TPAs that use or are negotiating to use the MRO's services. Under 49 CFR 40.123, the MRO acts as an independent and impartial "gatekeeper" for the accuracy and integrity of the drug testing process. How an MRO handles a laboratory result is covered in Why Does an MRO Contact an Employee after a DOT Drug Test?. MROs are one of the provider categories in the MyDrugTesting.com directory, which can be searched by location and service.
View →
Under 49 CFR 40.131, an MRO who receives a confirmed positive, adulterated, substituted or invalid result from the laboratory must contact the employee directly and on a confidential basis to find out whether the employee wants to discuss the result. The MRO explains that if the employee declines, the test will be verified as positive or as a refusal to test, as applicable. Staff under the MRO's personal supervision may make the first contact, but the rule limits them to scheduling the discussion and explaining the consequences of declining. Staff must not gather medical information. Reasonable efforts to reach the employee include at least three attempts spaced over a 24-hour period at the day and evening phone numbers on the CCF. If those efforts fail, the MRO directs the DER to tell the employee to contact the MRO, without telling the DER about the result. Under 49 CFR 40.133, the MRO may verify a result without an interview if the employee expressly declines, if more than 72 hours pass after a documented DER contact, or if neither the MRO nor the DER can reach the employee within ten days of the date the MRO receives the confirmed result from the laboratory. The MRO must then allow the employee to present information within 60 days of the verification to document that serious illness, injury or other circumstances unavoidably precluded contact, and the MRO may reopen the verification on that basis. For an invalid result, 49 CFR 40.133(b) provides that the MRO may instead verify the test as cancelled, with instructions to recollect immediately under direct observation. Related topics are covered in Who Can Be a Medical Review Officer for DOT Drug Tests? and Can a Prescription Explain a Positive DOT Drug Test?. The MyDrugTesting.com directory lists MROs and other drug testing providers that can be searched by location and service.
View →
In some cases. Under 49 CFR 40.137, the MRO considers whether an employee's legally valid prescription, consistent with the Controlled Substances Act, is a legitimate medical explanation for a confirmed positive result for drugs such as amphetamines or semi-synthetic opioids (hydrocodone, hydromorphone, oxycodone and oxymorphone). In making that decision, the MRO must not question whether the prescribing physician should have prescribed the substance. Section 40.137 states that the MRO offers the employee an opportunity to present a legitimate medical explanation in all cases, and the employee has the burden of proof. The information is presented at the verification interview, and the MRO may extend the time by up to five days when there is a reasonable basis to believe the employee can produce relevant evidence. If a legitimate medical explanation exists, the MRO verifies the result as negative. Otherwise, the MRO verifies it as positive. The rule allows a medication from a foreign country to be considered only if it was obtained legally there, has a legitimate medical use and was used for its intended medical purpose. Under 49 CFR 40.151(g), an MRO must not accept a legitimate medical explanation for PCP, 6-AM, MDMA or MDA. Section 40.137 also notes that when an MRO accepts a foreign medication explanation and verifies a test negative, the MRO may have a responsibility to raise fitness-for-duty considerations with the employer. Related topics are covered in Why Does an MRO Contact an Employee after a DOT Drug Test? and Does a State Medical Marijuana Card Excuse a Positive DOT Drug Test?. The MyDrugTesting.com directory can be searched by location and service to find MROs and other drug testing providers.
View →
Under 49 CFR 40.165, the MRO reports DOT drug test results to the employer's Designated Employer Representative (DER), or through a consortium/third-party administrator (C/TPA) when the employer has chosen to receive results that way. 49 CFR 40.3 states that the DER "receives test results and other communications for the employer." Under 49 CFR 40.321, employers and service agents are prohibited from releasing individual test results or medical information about an employee to third parties without the employee's specific written consent. The rule defines specific written consent as a statement signed by the employee agreeing to the release of a particular piece of information to a particular, explicitly identified person or organization at a particular time. Blanket releases, such as consent to release all test results or to release information to companies where the employee may apply for employment, are prohibited. The same section defines a third party as any person or organization that other subparts of Part 40 do not explicitly authorize or require to receive the information. Other sections of Subpart P set out exceptions to the general rule. Access to records is covered in Can an Employee Get a Copy of DOT Drug Test Records?. The MyDrugTesting.com directory lists TPAs, MROs and other drug testing service providers that can be searched by location and service.
View →
Yes. Under 49 CFR 40.329, an MRO or other service agent must provide copies of records about the employee's use of alcohol or drugs, including records of the employee's DOT-mandated drug and alcohol tests, within 10 business days of receiving a written request from the employee. A laboratory must provide the records relating to the results of the employee's drug test, such as the laboratory report and data package, within 10 business days of a written request from the employee that is made through the MRO. In both cases, the rule states that the provider "may charge no more than the cost of preparation and reproduction" for copies. A Substance Abuse Professional (SAP) must make a copy of all SAP reports available to the employee on request, with follow-up testing information redacted, according to the same section. Release of results to others is covered in Who Can Receive an Employee's DOT Drug Test Results?. MROs, laboratories and SAPs are among the provider types listed in the MyDrugTesting.com directory, which can be searched by location and service.
View →
Under 49 CFR 40.84, a laboratory testing the primary specimen keeps a specimen reported as positive, adulterated, substituted or invalid for a minimum of one year, in frozen storage that meets HHS requirements. Within that year, the MRO, the employee, the employer or a DOT agency may ask the laboratory in writing to keep the specimen for an additional period, for example to preserve evidence for litigation or a safety investigation, and the laboratory must comply. Without such a request, the rule states that the laboratory may discard the specimen at the end of the year. If the split specimen has not been sent to another laboratory, it is kept for the same period and under the same storage conditions as the primary specimen. A laboratory that tests a split specimen follows the same retention requirements for it. Related topics are covered in How Does a Split Specimen Test Work after a Positive DOT Drug Test? and How Is a DOT Urine Specimen Split and Sealed?. Laboratories are one of the provider categories in the MyDrugTesting.com directory, which can be searched by location and service.
View →
49 CFR 40.210 states that "Both urine and oral fluid specimens are authorized for collection and testing" under Part 40, and that only specimens screened and confirmed at HHS-certified laboratories are allowed. The same section states that point-of-collection urine tests, point-of-collection oral fluid tests, hair testing and instant tests "are not authorized." An employer uses one specimen type or the other at the beginning of a testing event, not both. If a problem in the collection requires a second collection, such as an insufficient quantity of urine or a temperature out of range, the rule allows a different specimen type to be chosen through the employer's standing order or a discussion with the collector, or by the employer's service agent when there is no standing order and the DER cannot be reached. Under 49 CFR 40.81, a U.S. laboratory may take part in DOT drug testing only if HHS certifies it under the National Laboratory Certification Program for each testing method it performs. Under 49 CFR 40.67(g)(5), oral fluid testing requires at least two HHS-certified oral fluid laboratories, and the HHS laboratory list published in the Federal Register on September 30, 2026 states that no laboratories are certified for oral fluid. Related topics are covered in How Is a Urine Specimen's Temperature Checked at a DOT Collection? and What Happens When an Employee Cannot Provide Enough Urine for a DOT Test?. The MyDrugTesting.com directory lists laboratories, collection sites and other drug testing providers that can be searched by location and service.
View →
No. Under current DOT guidance, a state medical marijuana card does not allow a Medical Review Officer (MRO) to verify a laboratory-confirmed marijuana positive DOT drug test as negative. Under 49 CFR 40.137(a), the MRO verifies a confirmed positive marijuana result unless the employee presents a legitimate medical explanation. Under 49 CFR 40.141(b), a prescription explanation depends on "a legally valid prescription consistent with the Controlled Substances Act." A Drug Enforcement Administration final rule published April 28, 2026 (91 FR 22714) placed FDA-approved drug products containing marijuana, and marijuana covered by a state medical marijuana license, in Schedule III of the Controlled Substances Act. Other marijuana remains in Schedule I. In Part 40 guidance last updated May 15, 2026, the DOT Office of Drug and Alcohol Policy and Compliance (ODAPC) stated that state-dispensed marijuana is still not an FDA-approved drug and cannot be prescribed. ODAPC also stated that state medical marijuana cards, physician recommendations or certifications, and dispensary records or receipts do not satisfy Part 40 requirements for a legitimate medical explanation. The same ODAPC guidance states that marijuana use is not compatible with safety-sensitive functions. Section 40.151(f) states that use of hemp or another non-prescription marijuana-related product "is not a legitimate medical explanation." Marijuana metabolites remain on the DOT test panel under 49 CFR 40.82. This answer applies to DOT-regulated tests under 49 CFR Part 40. Under 49 CFR 40.13(a), DOT tests "must be completely separate from non-DOT tests in all respects," and this answer does not address non-DOT tests. Related topics are covered in Can a Prescription Explain a Positive DOT Drug Test? and What Drugs Are Included in a DOT Drug Test?. Employers and employees can use the MyDrugTesting.com directory to search for MROs and other drug testing providers by location and service.
View →
49 CFR 40.191 lists the conduct that counts as a refusal to take a DOT drug test. Examples in the rule include failing to appear for a test, other than a pre-employment test, within a reasonable time after the employer's direction, failing to remain at the testing site until the testing process is complete, failing to provide a specimen and failing to permit a required observed or monitored collection. The list also includes declining an additional test the employer or collector directs, failing to undergo a medical evaluation directed by the MRO or the DER, failing to cooperate with any part of the testing process and admitting to the collector or MRO that the specimen was adulterated or substituted. A verified adulterated or substituted result is also a refusal. The rule states that an employee who leaves before the testing process begins for a pre-employment test has not refused. The collector notes conduct that may be a refusal on the CCF, but under 49 CFR 40.191(d)(1) the employer has the sole responsibility to decide whether a refusal occurred. For a pre-employment test, failing to undergo a directed medical evaluation counts as a refusal only if the test follows a contingent offer of employment. A refusal carries the consequences that DOT agency regulations set for a violation. Under 40.191(e), refusing a non-DOT test or declining to sign a non-DOT form is not a refusal of a DOT test. Related collection topics are covered in What Happens When an Employee Cannot Provide Enough Urine for a DOT Test? and When Is a DOT Urine Collection Directly Observed?. For motor carriers, Learn Laws® offers FMCSA Designated Employer Representative Training, which covers refusals under 49 CFR 40.191. Drug Testing listings in the MyDrugTesting.com directory can be narrowed by state.
View →
No. An instant drug test cannot be used for a DOT drug test. Under 49 CFR 40.210, only urine and oral fluid specimens screened and confirmed at HHS-certified laboratories are allowed for DOT drug testing, and point-of-collection (POC) urine tests, POC oral fluid tests, hair testing and instant tests "are not authorized." Under 49 CFR 40.81(a), a drug testing laboratory located in the U.S. may take part in DOT drug testing only if HHS certifies it under the National Laboratory Certification Program (NLCP) for each specimen testing methodology it performs. The DOT Office of Drug and Alcohol Policy and Compliance (ODAPC) adds on its laboratories page that HHS-certified Instrumented Initial Testing Facilities are not authorized for use in the DOT drug testing program. An employer that also uses instant tests under its own non-DOT policy keeps them apart from DOT testing. Under 49 CFR 40.13: DOT tests are completely separate from non-DOT tests in all respects (40.13(a)) The DOT test takes priority and is completed before a non-DOT test begins, and for a urine DOT test any excess urine is discarded and a separate void is collected for the non-DOT test (40.13(b)) No one may change or disregard the results of DOT tests based on the results of non-DOT tests (40.13(f)) The Federal CCF is not used in non-DOT testing programs (40.13(g)) Learn Laws® offers Non-DOT Urine Specimen Collector Training, an online non-DOT urine collector course on collect-only tests, instant rapid-dip panels, chain of custody, state law and live virtual mock collections. Probation Testing is named in the services of many Drug Testing listings on MyDrugTesting.com.
View →
A screening test is the first test, used to separate negative results from those that need more testing. A confirmation test is a second, separate test that checks a screening result at or above the cutoff. Under 49 CFR Part 40, both DOT drug tests and DOT alcohol tests use the two steps, but the steps work differently for each. For drug tests, Part 40 calls the screening step an initial drug test. Under 49 CFR 40.3, an initial drug test is "The first test used to differentiate a negative specimen from one that requires further testing for drugs or drug metabolites," and a confirmatory drug test is "A second analytical procedure performed on a different aliquot of the original specimen to identify and quantify a specific drug or drug metabolite." Both steps take place at the laboratory, because 49 CFR 40.210 allows only specimens screened and confirmed at HHS-certified laboratories. A confirmed laboratory result is not yet the final result. Under the 40.3 definition of a verified test, a laboratory result is verified only after review and final determination by the Medical Review Officer (MRO). For alcohol tests, the screening test can use breath or saliva, and the confirmation test uses breath only. Under 49 CFR Part 40: A screening test determines whether an employee may have a prohibited concentration of alcohol in a breath or saliva specimen (40.3) A screening result of less than 0.02 goes to the DER, and a result of 0.02 or higher leads to a confirmation test (40.247) The confirmation test uses an evidential breath testing device (EBT) and provides quantitative data about the alcohol concentration (40.3) The waiting period before the confirmation test lasts at least 15 minutes from the end of the screening test, and the confirmation test should begin as soon as possible, but not more than 30 minutes after the screening test is completed (40.251(a)(1)) Only saliva or breath for screening tests and breath for confirmation tests, using approved devices, are permitted (40.277) Learn Laws® offers DOT Breath Alcohol Technician Training, an online course with Model BAT Course training, EBT device training and seven live mock tests under 49 CFR 40.213. Several Drug Testing profiles in the MyDrugTesting.com directory list both Saliva Alcohol Screening and Evidential Breath Alcohol Testing (EBT) among their services.
View →
In drug testing, a panel is a drug or class of drugs that a test covers, and a multi-panel test covers more than one. Part 40 does not use the term, but the DOT Office of Drug and Alcohol Policy and Compliance (ODAPC) does. ODAPC describes DOT testing at HHS-certified laboratories as "a 5-panel drug test regimen," with the five panels being marijuana (THC), cocaine, amphetamines, opioids and phencyclidine (PCP). Under 49 CFR 40.82, laboratories test DOT specimens for these five drugs or classes of drugs. A single panel can cover several specific drugs. The urine cutoff table in 49 CFR 40.85 lists confirmatory test analytes such as codeine, morphine, 6-acetylmorphine, hydrocodone, hydromorphone, oxycodone and oxymorphone, which ODAPC's 5-panel notice places under opioids, and amphetamine, methamphetamine, MDMA and MDA, which it places under amphetamines. ODAPC's 5-panel notice states that collectors check the 5-panel box in Step 1 of the CCF, the box specified for "THC, COC, PCP, OPI, AMP." An employer or laboratory cannot expand the DOT panel. Under 40.82, laboratories "must not test 'DOT specimens' for any other drugs," and 49 CFR 40.13(c) gives the example that a DOT specimen must not be tested for additional drugs. An employer that wants other drugs tested under its own policy uses a non-DOT test, which under 40.13: Is completely separate from the DOT test in all respects (40.13(a)) Begins only after the DOT test is completed, with a separate urine void for a urine test (40.13(b)) Does not use the Federal CCF (40.13(g)) Instant multi-panel cups and larger panels, such as 10-panel tests, are non-DOT tests, because 49 CFR 40.82 limits DOT testing to five drugs or classes of drugs and 49 CFR 40.210 does not authorize instant tests. Learn Laws® offers DOT Urine Specimen Collector Training, an online course with qualification training and five live mock collections under 49 CFR 40.33. A Night/Weekend Availability tag appears in the services of some Drug Testing profiles on MyDrugTesting.com.
View →
No. DOT drug tests do not check for nicotine. Under 49 CFR 40.82, laboratories test DOT specimens for five drugs or classes of drugs, marijuana metabolites, cocaine metabolites, amphetamines, opioids and phencyclidine (PCP), and "must not test 'DOT specimens' for any other drugs." Nicotine is not on that list, and it is not among the drugs named in the definition of drugs in 49 CFR 40.3. The only use of the word tobacco in Part 40 is in 49 CFR 40.72(a), where the collector checks the employee's mouth for items such as tobacco that could interfere with an oral fluid collection. Apart from medical tests tied to a physical examination required by DOT agency regulations under 40.13(d), 49 CFR 40.13(c) bars any tests on DOT specimens other than those specifically authorized by Part 40 or DOT agency regulations, and gives the example that a DOT specimen must not be tested for additional drugs. Any nicotine or tobacco test an employer runs is outside the DOT program. Under 40.13, such a non-DOT test: Is completely separate from the DOT test in all respects (40.13(a)) Is conducted only after the DOT test is completed, with a separate urine void for a urine test (40.13(b)) Does not use the Federal CCF (40.13(g)) Part 40 does not address whether an employer may test for nicotine under its own policy. Learn Laws® offers Non-DOT Designated Employer Representative Training (DER), a course of about two hours for those who run a non-DOT drug and alcohol testing program under company policy and state law. Many Drug Testing profiles in the MyDrugTesting.com directory name the specimen types a provider collects, such as Urine, Hair or Oral Fluid, in a Services section.
View →
An MDMA drug test looks for the specified MDMA target in a biological sample. MDMA is the abbreviation for methylenedioxymethamphetamine, also called ecstasy. Drug tests look for particular drugs or their metabolites rather than providing a complete inventory of substances in the body. The test description identifies the substances included in that analysis. A test of a person is different from testing a substance or tablet. NIDA distinguishes drug testing of a biological sample from drug checking, which examines the chemicals in a substance. This FAQ addresses specimens collected from a person. It does not describe identification of tablets, assessment of a product’s contents, or whether a substance is safe to consume. The name of a broad drug category does not explain each analytical target. As a specific example, the DOT urine testing table lists MDMA and MDA together for initial testing and separately as confirmatory analytes. The same table spells out MDA as methylenedioxyamphetamine. These are named targets within that regulated testing table, not a general description of retail kits or private testing panels. An initial screening result is different from a confirmed result. NIDA explains that initial tests identify possible drug use, while confirmatory tests can verify or refute a screening finding. FDA includes ecstasy among the drugs detected by some home urine tests and emphasizes checking the label for the specific drug of interest. FDA also describes those home tests as qualitative, meaning that they indicate possible presence rather than the amount present. A result has further limits. NIDA states that urine drug tests do not establish the time since last ingestion, the overall duration of use, or the state of intoxication. Drug testing also does not diagnose a substance use disorder. This answer does not interpret an individual MDMA result or determine fitness for work. Sources NIDA: Drug Testing FDA: Drugs of Abuse (Collection Kit) eCFR: 49 CFR 40.85: What are the cutoff concentrations for urine drug tests? FDA: Drugs of Abuse Home Use Test
View →
Preemployment drug testing for oil field work is drug screening connected with hiring for a position. The relevant distinction is the position and testing program, rather than the industry label alone. Employers may use drug testing as part of a workplace program. Some work also falls within federal transportation testing rules, including covered pipeline functions. SAMHSA distinguishes general private employment from industries and positions subject to specific federal requirements. It explains that most private employers are not required to have a workplace drug policy, while identifying exceptions for federal contractors and grantees and for safety and security sensitive industries and positions. A statement about a workplace policy is not the same as a statement prescribing an identical drug test for applicants. Pipeline work provides a specific example. PHMSA describes Part 199 testing as applying to covered employees at pipeline facilities subject to Parts 192, 193 and 195. Its overview identifies covered functions as regulated operations, maintenance or emergency response work on a pipeline or liquefied natural gas facility. Covered employees can include operator personnel and contractor personnel. PHMSA includes preemployment testing for hires and employees transferring into covered positions in its program overview. Section 199.105(a) describes the preemployment condition as passing a drug test or being covered by an anti drug program that conforms to Part 199. This is a description of that provision and its alternative, not a determination that a particular oil field position is covered. The testing program also matters to the method. PHMSA states that required testing uses DOT procedures in Part 40. Section 40.210 describes laboratory screening and confirmation and excludes instant drug tests from that program. This overview does not select a panel or specimen, determine a job’s regulatory status, or provide instructions for satisfying an employer’s testing requirements. Sources NIDA: Drug Testing PHMSA: Drug and Alcohol Testing Program Overview SAMHSA: Federal Laws and Regulations eCFR: 49 CFR 199.105: Drug tests required. eCFR: 49 CFR 40.210: What kinds of drug tests are permitted under the regulations?
View →
Home drug tests can indicate possible drug presence, but a screening result does not diagnose a substance use disorder. For teenagers, the test’s analytical limits are separate from questions about consent and privacy. This overview describes those distinctions without recommending whether a parent should test a teenager or deciding who can authorize a particular test. FDA explains that home urine tests are qualitative. They indicate whether a particular drug may be present rather than how much is present. The label identifies the substances the test is designed to detect. A positive home screening result is preliminary, and FDA emphasizes laboratory confirmation because medicines and other factors can affect the result. A positive result for a prescribed medicine does not establish misuse. A negative result also has limits. FDA notes that testing for the wrong drug, specimen timing, improper storage and expired test chemicals can produce negative findings despite drug use. NIDA adds that urine drug tests do not establish intoxication or the overall duration of use. A home test therefore supplies a limited analytical finding rather than a complete explanation of a teenager’s health or behavior. Consent to care and access to health information are distinct questions. HHS explains that parents generally have access to a minor child’s medical records under the HIPAA Privacy Rule when consistent with applicable law, but describes exceptions. These include some situations in which a minor consents to care without required parental consent and situations involving an agreed confidential relationship with a provider. HHS adds that even in those situations, state or other applicable law may require, permit or prohibit parental access. These medical record rules are not blanket permission for home testing. In a 2019 NIDA video on adolescent screening in primary care, Dr. Geetha Subramaniam emphasizes privacy and explaining when information may be shared with parents. That clinical discussion does not establish a nationwide consent rule for retail home testing. This answer does not determine a family’s authority to obtain a specimen, access results or disclose information. Those questions remain outside this general explanation. Sources FDA: Drugs of Abuse Home Use Test NIDA: Drug Testing HHS: Does the HIPAA Privacy Rule allow parents the right to see their children’s medical records? NIDA: Adolescent Substance Use Screening tools in Primary Care Settings NIDA: Screening Tools for Adolescent Substance Use
View →
Home mouth swab drug tests use oral fluid, commonly called saliva, as the specimen. Home testing can mean either a rapid test performed at home or a collection kit whose sample is sent to a laboratory. The location where a sample is collected does not, by itself, identify where the analysis takes place. MedlinePlus, a service of the National Library of Medicine, describes these two home testing formats separately. A rapid home test produces a screening result at home. A self collection kit gathers saliva or another specimen for analysis elsewhere. FDA’s collection kit explanation likewise includes saliva among the materials that can be collected and shipped to a laboratory. The laboratory performs preliminary analysis and additional testing when the screen suggests possible drug presence. The specimen type does not identify the complete drug panel. NIDA explains that drug tests target particular drugs or drug classes above a specified cutoff. A saliva test therefore answers a question about the targets included in that test, rather than providing a complete substance inventory. The kit’s stated specimen and analytical targets are different details from whether it provides a rapid screen or laboratory analysis. Screening and confirmation are also different stages. MedlinePlus explains that a positive home test needs laboratory follow up to check the result’s accuracy. FDA notes that a negative collection kit result may occur when the specimen does not contain detectable drugs at the time of collection. Neither result supplies a diagnosis of a substance use disorder, which NIDA distinguishes from drug testing. This consumer explanation is separate from DOT oral fluid testing. Section 40.210 describes DOT drug testing using specimens screened and confirmed at HHS certified laboratories and excludes instant and point of collection oral fluid tests. This FAQ does not address the availability of DOT oral fluid testing, collector qualifications, or how to conduct a regulated collection. Sources NIDA: Drug Testing MedlinePlus: Drug Testing FDA: Drugs of Abuse (Collection Kit) eCFR: 49 CFR 40.210: What kinds of drug tests are permitted under the regulations?
View →
Ready to get started?